MARK G FOLETTA
CIK 1236389 · EVP & Chief Financial Officer · last filed 2026-08-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.47M
Companies
10
Total Filings
130
Lifetime Open-Market Net
-$8.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DXCM | Director | 57,183 | $89.39 | $5.11M | -$5.96M | 39 | 2026-08-04 |
| AMN | Director | 41,515 | $32.78 | $1.36M | -$1.20M | 21 | 2026-06-17 |
| ENTA | Director | — | $13.64 | — | $0 | 7 | 2026-03-13 |
| Forte Biosciences, Inc. (TOCA) Delisted | EVP & Chief Financial Officer | 1,003 | — | — | $71.5K | 7 | 2019-10-04 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 683 | $8.16 | $5.6K | $76.4K | 7 | 2017-12-06 |
| AMN HEALTHCARE SERVICES INC (AHS) Delisted | Director | 5,532 | — | — | $0 | 4 | 2016-04-22 |
| BIOCEPT INC (BIOC) Delisted | Interim CFO | — | $0.43 | — | $0 | 1 | 2015-09-02 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 2 | 2014-11-12 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | SVP, Chief Financial Officer | 81,344 | — | — | -$1.48M | 25 | 2012-07-26 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | — | — | — | $0 | 6 | 2011-05-27 |
Recent Filings · Page 7 of 13
130 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-05-17 | DXCM | Sell (S) | −1,000 | -$121.9K | EDGAR |
| 2019-04-19 | AMN | Mixed | +2,153 | $0 | EDGAR |
| 2019-04-17 | DXCM | Sell (S) | −1,000 | -$119.0K | EDGAR |
| 2019-03-19 | DXCM | Sell (S) | −1,000 | -$150.3K | EDGAR |
| 2019-03-05 | Forte Biosciences, Inc. (TOCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-02-20 | DXCM | Sell (S) | −1,000 | -$148.7K | EDGAR |
| 2018-08-28 | DXCM | Sell (S) | −1,000 | -$137.5K | EDGAR |
| 2018-06-26 | DXCM | Grant (A) | +4,052 | $4 | EDGAR |
| 2018-06-04 | DXCM | Grant (A) | +4,062 | $4 | EDGAR |
| 2018-04-20 | AMN | Mixed | +3,365 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.